This retrospective study showed that PD-1 inhibitors appear to be a suitable option for the treatment of patients with locally advanced or metastatic cSCC, This applies also to elderly and immune-suppressed patients, albeit with consideration of the high drug toxicity. This evidence concerns the gene PDCD1 and skin squamous cell carcinoma.